COMMUNIQUÉS West-GlobeNewswire

-
Ambu A/S: Financial Diary
29/09/2017 - 13:05 -
Total number of shares and voting rights in Zealand at September 30, 2017
29/09/2017 - 10:49 -
To Enable Better Targeting Of Resources, Skåne University Hospital Starts To Use New Acarix CADScor®System For Early Rule-Out Of Coronary Artery Disease (CAD)
29/09/2017 - 09:00 -
Solon Eiendom ASA : Primary insider notification
29/09/2017 - 08:30 -
DXS International plc : Final Results
29/09/2017 - 08:15 -
Prothena Reports Results from Phase 1b Multiple Ascending Dose Study of PRX003 in Patients with Psoriasis
28/09/2017 - 22:05 -
AB Science annonce que des données cliniques et précliniques du masitinib dans la SLA ont été retenues pour être présentées oralement lors de 6 conférences internationales en 2017
28/09/2017 - 20:01 -
AB Science announces that abstracts reporting on clinical and preclinical data of masitinib in the treatment of ALS, have been selected for presentation at 6 major international meetings during 2017
28/09/2017 - 20:01 -
Sébastien Dallais nommé Directeur Commercial et Marketing France de Medasys
28/09/2017 - 18:35 -
HALF-YEAR CONSOLIDATED RESULTS: STABILITY OF NET LOSS & MAJOR PROGRESS ON R&D PROGRAMS
28/09/2017 - 18:30 -
NANOBIOTIX prévoit de lancer aux Etats-Unis son premier essai clinique avec NBTXR3 en combinaison avec des « immune checkpoints inhibitors »
28/09/2017 - 18:29 -
NANOBIOTIX plans to conduct its first clinical trial with NBTXR3 in combination with immune checkpoint inhibitors in the U.S.
28/09/2017 - 18:29 -
Summit Therapeutics plc : Exercise of Share Options
28/09/2017 - 18:15 -
ThromboGenics NV : ThromboGenics Successfully Introduces New 'Already-Diluted' Formulation of JETREA® (ocriplasmin) in the US
28/09/2017 - 17:35 -
UPDATE ON VOLUNTARY OFFER FOR WEIFA ASA - ACCEPTANCES AT APPROXIMATELY 90.3 %
28/09/2017 - 16:00 -
Terveystalo Plc applies for its shares to be listed on the Official List of Nasdaq Helsinki Ltd
28/09/2017 - 14:55 -
Auris Medical Announces Transfer to Nasdaq Capital Market
28/09/2017 - 14:30 -
ProMIS Neurosciences Chief Scientific Officer, Dr. Neil Cashman, to Present at Third Annual R&D Technologies Conference
28/09/2017 - 13:30 -
Allergy Therapeutics: Preliminary Results
28/09/2017 - 13:00
Pages